Clinical Trial Update: Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

This trial update reports Phase 1/2 results for the combination of cediranib and olaparib in recurrent ovarian, fallopian tube, or primary peritoneal cancer and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Cediranib (Cediranib)
• Olaparib (Olaparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Fallopian Tube Carcinoma, Ovarian Endometrioid Adenocarcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2020-07-22